PRIMAVERA

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

01.11.2021 bis 31.10.2026

PrIMAVeRa is a European project funded by the Innovative Medicines Initiative 2 (IMI2) dedicated to harnessing the power of big data and AI to steer the fight against antimicrobial resistance. The project aims to develop an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes) to predict the impact of vaccines and mAbs on the reduction of AMR. This platform will enable policymakers to reach data-driven decisions regarding prioritisation of specific vaccines and mAbs, informing the strategic allocation of limited resources. The following main areas will be addressed by PrIMAVeRa in an integrated manner: Assessment of the availability and quality of published data and existing mathematical models of AMR; Setting up a comprehensive epidemiological repository; Development of an improved mathematical models of AMR including cost-effectiveness analyses (CEA); Establishment of a plan for evaluation of the models in multi-country settings.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.